Cargando…

Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology

Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sjögren, Magnus, Huttunen, Henri J., Svenningsson, Per, Widner, Håkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535305/ https://www.ncbi.nlm.nih.gov/pubmed/34680924 http://dx.doi.org/10.3390/genes12101529

Ejemplares similares

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
por: Svenningsson, Per, et al.
Publicado: (2015)

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort
por: Brolin, Kajsa, et al.
Publicado: (2022)

CDNF Protein Therapy in Parkinson’s Disease
por: Huttunen, Henri J., et al.
Publicado: (2019)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Antidepressant-like properties of sarizotan in experimental Parkinsonism
por: Zhang, Xiaoqun, et al.
Publicado: (2011)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
por: Wallin, Johan, et al.
Publicado: (2021)

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease
por: Jaiteh, Mariama, et al.
Publicado: (2018)

Analogies in Oncology: Explanations Made Easier
por: Vogel, Wendy H.
Publicado: (2015)

Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson’s disease
por: Waldthaler, Josefine, et al.
Publicado: (2019)

Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist’s Treatment Decisions?—An Observational Study in Routine Clinical Care of People with Parkinson’s Disease
por: Sundgren, Mathias, et al.
Publicado: (2021)

A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism
por: Papathoma, Paraskevi-Evita, et al.
Publicado: (2022)

Patients’ views on using human embryonic stem cells to treat Parkinson’s disease: an interview study
por: Drevin, Jennifer, et al.
Publicado: (2022)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018)

Impaired migratory phenotype of CD4(+) T cells in Parkinson’s disease
por: Mamula, Dejan, et al.
Publicado: (2022)

Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis
por: Widner, Håkan, et al.
Publicado: (1988)

Feasibility Aspects of Exploring Exercise-Induced Neuroplasticity in Parkinson's Disease: A Pilot Randomized Controlled Trial
por: Johansson, Hanna, et al.
Publicado: (2020)

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study
por: Surova, Yulia, et al.
Publicado: (2018)

Patient-driven N-of-1 in Parkinson’s Disease: Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia
por: Riggare, Sara, et al.
Publicado: (2017)

Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease
por: Ran, Caroline, et al.
Publicado: (2017)

Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson’s Disease
por: Green, Holly F., et al.
Publicado: (2019)

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease
por: Surova, Yulia, et al.
Publicado: (2016)

Cortex-wide topography of 1/f-exponent in Parkinson’s disease
por: Helson, Pascal, et al.
Publicado: (2023)

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
por: Björkhem, Ingemar, et al.
Publicado: (2018)

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson’s Disease with Comorbid Depression versus Patients with Major Depressive Disorder
por: Svenningsson, Per, et al.
Publicado: (2017)

Pupil light reflex dynamics in Parkinson’s disease
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
por: Green, Holly, et al.
Publicado: (2019)

Reading Alterations in Parkinson's Disease Indicate Worse Cognitive Status
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism
por: Monnot, Cyril, et al.
Publicado: (2017)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Hyperkinesias and Echolalia in Primary Familial Brain Calcification
por: Paucar, Martin, et al.
Publicado: (2020)

Individually Tailored Internet-Based Cognitive-Behavioral Therapy for Daily Functioning in Patients with Parkinson’s Disease: A Randomized Controlled Trial
por: Kraepelien, Martin, et al.
Publicado: (2020)

Molecular genetics made simple
por: Kassem, Heba Sh., et al.
Publicado: (2012)

Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience
por: Zahrieh, David, et al.
Publicado: (2022)

MCEE Mutations in an Adult Patient with Parkinson’s Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid
por: Andréasson, Mattias, et al.
Publicado: (2019)

The Few Who Made It: Commercially and Clinically Successful Innovative Bone Grafts
por: Sallent, Ignacio, et al.
Publicado: (2020)

Teams: learning made simple
por: Partridge, Lesley
Publicado: (2007)

GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients
por: Baek, Jean-Ha, et al.
Publicado: (2019)

Synaptic proteins in CSF relate to Parkinson’s disease stage markers
por: Bereczki, Erika, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ld4ju7lqivql67p4n2qeuf7pbr